Aldosterone Synthase Inhibitor Effective for Reducing Albuminuria
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 18, 2023 -- An aldosterone synthase inhibitor, BI 690517, reduces albuminuria, according to a study published online Dec. 15 in The Lancet.
Katherine R. Tuttle, M.D., from the University of Washington in Seattle, and colleagues enrolled adults with an estimated glomerular filtration rate ≥30 and <90 mL/min/1.73 m2, urine albumin:creatinine ratio (UACR) ≥200 and <5,000 mg/g, and serum potassium ≤4.8 mmol/L, taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Patients were randomly assigned to eight weeks of empagliflozin or placebo run-in. Participants were then re-randomly assigned to once-daily BI 690517 at a dose of 3, 10, or 20 mg or placebo for 14 weeks. The change in UACR from the second randomization to the end of treatment was the primary end point.
Overall, 586 of the 714 run-in participants were randomly assigned to BI 690517 or placebo. The researchers found that the percent change in UACR was −3, −22, −39, and −37 percent with placebo and BI 690517 3-, 10-, and 20-mg monotherapy, respectively. When added to empagliflozin, BI 690517 produced similar UACR reductions. In 10, 15, and 18 percent of participants receiving BI 690517 at doses of 3, 10, and 20 mg, respectively, and in 6 percent of those receiving placebo, with or without empagliflozin, investigator-reported hyperkalemia occurred.
"Using BI 690517 along with empagliflozin may offer the potential for additive kidney protection, while mitigating hyperkalemia risk," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Boehringer Ingelheim, which is developing BI 690517 and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Simple Risk Score Predicts Severe Cisplatin-Linked Acute Kidney Injury
WEDNESDAY, March 27, 2024 -- A simple risk score consisting of nine covariates predicts the risk for severe cisplatin-associated acute kidney injury (CP-AKI), according to a study...
Metabolic, Bariatric Surgery Provides Pathway to Transplant in ESRD
TUESDAY, March 12, 2024 -- Referral of obese end-stage renal disease (ESRD) patients to metabolic and bariatric surgery (MBS) could offer a pathway to transplant, according to a...
Similar Management Seen for Dialysis-Requiring AKI, ESKD Patients
THURSDAY, Oct. 5, 2023 -- Patients with dialysis-requiring acute kidney injury (AKI-D) are prescribed the same dialysis as end-stage kidney disease (ESKD) patients, but some AKI-D...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.